Jupiter Neurosciences: Innovative Resveratrol Platform Tackles Neuroinflammation & Rare CNS Diseases

Jupiter Neurosciences, Inc. (Nasdaq: JUNS) is a clinical-stage pharmaceutical company pioneering treatments for neuroinflammation and rare diseases through its proprietary resveratrol delivery platform. Its lead product, JOTROL™, offers groundbreaking bioavailability—nine times greater than traditional resveratrol formulations—enabling safe, effective treatment for CNS disorders like Alzheimer's and Parkinson's. Backed by elite research partnerships and a robust clinical pipeline, including multiple Phase 2 trials expected to launch within the next 12 months, Jupiter is also advancing a near-term direct-to-consumer revenue opportunity in nutraceuticals, positioning the company as a transformative force in both pharmaceutical and consumer health markets. ------------------------------------------------------------------- 🌐 Want more market-moving insights? Dive deeper at www.benzinga.com — your one-stop destination for the latest financial news, data, and expert analysis to stay ahead of the markets. 📲 Let’s stay connected! Follow us for real-time updates, market tips, and exclusive content: 🔹 Instagram: https://www.instagram.com/benzinga 🔹 Facebook: https://www.facebook.com/benzinga 🔹 TikTok: https://www.tiktok.com/@benzinga 🔹 X: https://www.x.com/benzinga ⚠️ Disclaimer: Investing in financial markets carries risk, and there are no guaranteed returns. All information is for educational purposes only and should not be taken as financial advice. Always do your own research and speak with a qualified financial advisor before making investment decisions. Only invest what you can afford to lose. Past performance does not guarantee future outcomes.